Core Viewpoint - The company currently has one synthetic biology and biocatalysis technology center, which includes a synthetic biology technology innovation laboratory focused on developing functional proteins for feed and sweeteners for food [1] Group 1 - The synthetic biology technology innovation laboratory is primarily used for research and development of functional proteins for animal feed and sweeteners for food [1] - The laboratory has a limited number of R&D projects, small investment amounts, and insufficient professional personnel, indicating it is still in the early stages of strain laboratory research [1] - There is a significant gap to scale-up production, and the laboratory does not currently meet industrialization conditions [1]

天眼查App显示，近日，阿普罗（南京）生物技术有限公司成立，法定代表人为李彬，注册资本500万 人民币，经营范围为一般项目：农业科学研究和试验发展；肥料销售；生物有机肥料研发；复合微生物 肥料研发；土壤与肥料的复混加工；化肥销售；海洋生物活性物质提取、纯化、合成技术研发；技术服 务、技术开发、技术咨询、技术交流、技术转让、技术推广；工程和技术研究和试验发展（除人体干细 胞、基因诊断与治疗技术开发和应用，中国稀有和特有的珍贵优良品种）；生物基材料技术研发；生物 化工产品技术研发；货物进出口（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。 ...

Core Insights - Hebei Water Particle Biological Technology Co., Ltd. has been established with a registered capital of 5 million RMB [1] Company Overview - The legal representative of the company is Zhang Yongjie [1] - The company operates in various sectors including technology services, biological materials manufacturing, and agricultural pollution prevention [1] Business Scope - General projects include technology services, development, consulting, and transfer, as well as manufacturing and sales of bio-based materials and plastic products [1] - The company is involved in the sales of chemical products (excluding licensed chemical products), food-grade plastic packaging containers, fertilizers, and bio-organic fertilizers [1] - The company also focuses on soil and fertilizer remediation, agricultural pollution prevention technologies, and research and development in biological chemical products [1] - Licensed projects include the production of food additives, which require approval from relevant authorities before operation [1]

8月19日消息，天眼查融资历程显示，苏州一兮生物技术有限公司近日获得"A轮"融资，涉及融资金额 近2亿人民币，投资机构为黄山新安江。 来源：金融界 资料显示，苏州一兮生物技术有限公司法定代表人为刘振云，成立于2019年，位于苏州市，是一家以从 事研究和试验发展为主的企业。企业注册资本619.466841万人民币，并已于2025年完成了A轮，交易金 额近2亿人民币。 通过天眼查大数据分析，苏州一兮生物技术有限公司共对外投资了1家企业，知识产权方面有商标信息 29条，专利信息35条，此外企业还拥有行政许可4个。 天眼查信息显示，苏州一兮生物技术有限公司的股东为：刘振云、苏州一塔企业管理合伙企业（有限合 伙）、Vitalbridge YX Limited、苏州市正轩前瞻志合创业投资合伙企业（有限合伙）、苏州湖图企业管 理合伙企业（有限合伙）。 ...

Core Insights - A new company, Jinhe Aichongyi (Shanghai) Biotechnology Co., Ltd., has been established with a registered capital of 10 million yuan [1] - The company's business scope includes medical research and experimental development, cell technology research and application, and internet information services for pharmaceuticals [1] - Jinhe Aichongyi is wholly owned by Jinhe Biology (002688) [1]

天眼查App显示，近日，黑龙江粒粒壮生物技术有限公司成立，法定代表人为俞柯伟，注册资本666万 人民币，经营范围为一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；生 态环境材料制造；农林废物资源化无害化利用技术研发；生物有机肥料研发；新材料技术研发；生物基 材料技术研发；资源循环利用服务技术咨询；防洪除涝设施管理；工程管理服务；农业面源和重金属污 染防治技术服务；生态恢复及生态保护服务；环保咨询服务；土壤环境污染防治服务；新材料技术推广 服务；水污染治理；园林绿化工程施工；土石方工程施工；土壤与肥料的复混加工；建筑材料销售；生 态环境材料销售；金属材料销售；肥料销售；化肥销售；生物基材料销售。（除依法须经批准的项目 外，凭营业执照依法自主开展经营活动）许可项目：建设工程施工；河道疏浚施工专业作业；建筑劳务 分包。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文 件或许可证件为准）。 ...

通过天眼查大数据分析，诺未生物技术（无锡）有限公司共对外投资了2家企业，专利信息12条，此外 企业还拥有行政许可2个。 天眼查信息显示，诺未生物技术（无锡）有限公司的股东为：王晓芳、北京诺未生物科技合伙企业（有 限合伙）、北京国信海翔股权投资合伙企业（有限合伙）、北京诺未科技发展合伙企业（有限合伙）、 北京行致远科技合伙企业（有限合伙）。 来源：金融界 7月25日消息，天眼查融资历程显示，诺未生物技术（无锡）有限公司近日获得"B+轮"融资，涉及融资 金额数千万人民币，投资机构为天津博通创投，锡创投。 资料显示，诺未生物技术（无锡）有限公司法定代表人为王晓芳，成立于2023年，位于无锡市，是一家 以从事研究和试验发展为主的企业。企业注册资本1509.968216万人民币，并已于2025年完成了B+轮， 交易金额数千万人民币。 ...

Group 1 - MIRXES-B (02629.HK) plans to globally offer 46.62 million shares, with 4.662 million shares available in Hong Kong and 41.958 million shares for international offering [1] - The subscription period is from May 15 to May 20, with a maximum offer price of HKD 23.30 per share and an entry fee of approximately HKD 2,353.49 for 100 shares [1] - The total expected fundraising amount is HKD 1.086 billion, with a net amount of HKD 881 million, intended for the development, regulatory filing, production, and commercialization of the core product GASTROClearTM [1] Group 2 - The company aims to enhance its "end-to-end" capabilities to capture significant commercial potential within the value chain and to fund ongoing and planned research and development [1] - Key cornerstone investors include Beijing Xunrui Enterprise Management Partnership (Limited Partnership) and Evergreen Gate Limited, which will subscribe to approximately 19.287 million shares at the offer price [1] - MIRXES-B is expected to be listed on the main board on May 23, 2025, with China International Capital Corporation Hong Kong Securities Limited and Jianyin International Financial Limited serving as joint sponsors [1] Group 3 - The company reported net profits of -56.6416 million USD, -69.2250 million USD, and -92.3270 million USD for the years ending December 31, 2022, 2023, and 2024, respectively, with year-on-year changes of -1738.36%, -22.22%, and -33.37% [2]